AngioDynamics, Inc. (NASDAQ:ANGO) Given Average Rating of “Hold” by Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received an average recommendation of “Hold” from the five ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $21.50.

A number of equities analysts recently issued reports on ANGO shares. Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating and set a $20.00 target price for the company in a research note on Tuesday, June 4th. BidaskClub lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 30th. ValuEngine upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd. Finally, TheStreet lowered AngioDynamics from a “b” rating to a “c” rating in a research note on Monday, July 29th.

In other AngioDynamics news, Director Kevin J. Gould sold 13,650 shares of AngioDynamics stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $21.45, for a total transaction of $292,792.50. Following the completion of the transaction, the director now owns 61,774 shares in the company, valued at approximately $1,325,052.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.80% of the company’s stock.



Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Metropolitan Life Insurance Co. NY raised its stake in shares of AngioDynamics by 417.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,559 shares of the medical instruments supplier’s stock valued at $253,000 after buying an additional 10,130 shares during the last quarter. South Dakota Investment Council increased its stake in shares of AngioDynamics by 53.4% in the 1st quarter. South Dakota Investment Council now owns 15,800 shares of the medical instruments supplier’s stock valued at $361,000 after purchasing an additional 5,500 shares in the last quarter. Tibra Equities Europe Ltd purchased a new position in shares of AngioDynamics in the 1st quarter valued at about $245,000. Perkins Capital Management Inc. increased its stake in shares of AngioDynamics by 19.0% in the 1st quarter. Perkins Capital Management Inc. now owns 45,750 shares of the medical instruments supplier’s stock valued at $1,046,000 after purchasing an additional 7,300 shares in the last quarter. Finally, Tributary Capital Management LLC increased its stake in shares of AngioDynamics by 39.9% in the 1st quarter. Tributary Capital Management LLC now owns 704,499 shares of the medical instruments supplier’s stock valued at $16,105,000 after purchasing an additional 200,829 shares in the last quarter. Institutional investors and hedge funds own 98.37% of the company’s stock.

Shares of AngioDynamics stock traded down $0.41 during trading on Wednesday, reaching $18.70. The company’s stock had a trading volume of 189,500 shares, compared to its average volume of 220,351. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.75 and a current ratio of 4.30. The stock has a market capitalization of $712.36 million, a P/E ratio of 22.40 and a beta of 0.66. AngioDynamics has a 1-year low of $18.11 and a 1-year high of $25.48. The company has a 50-day moving average price of $20.49.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.01). The business had revenue of $96.30 million during the quarter, compared to analyst estimates of $92.34 million. AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.20 EPS. As a group, equities analysts predict that AngioDynamics will post 0.27 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Story: How to Invest in Marijuana Stocks

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.